TCG Crossover Management, LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), TCG Crossover Management, LLC reported 33 stock positions worth $1.3 billion. Its top holding was CG Oncology (CGON) at 12.4% of the portfolio, followed by Dyne Therapeutics (DYN, 5.9%) and Astria Therapeutics (ATXS, 5.9%). Compared with Q4 2023, it opened 9 new positions, sold out of 5, added to 5 and reduced 7. The biggest buy was a new position in CG Oncology (CGON) and the biggest sale an exit from Icosavax (ICVX).
- Most Recent 13F
- Q2 2026
- Location
- PALO ALTO, CA
- CIK
- 0001839948
- Portfolio Value
- $1.3B (Q1 2024)
- SEC Filing
- 0001214659-24-009128 ↗ filed May 15, 2024
Holdings Value
Holdings 33 stocks · $1.3B
| CGON CG Oncology Inc. | 12.39% | 3,570,206 | $156.7M | New |
| DYN Dyne Therapeutics Inc. | 5.95% | 2,650,150 | $75.2M | Add +60.6% |
| ATXS Astria Therapeutics Inc. | 5.87% | 5,278,928 | $74.3M | New |
| SLN Silence Therapeutics PLC-ADR | 5.63% | 3,295,350 | $71.2M | Add +56.6% |
| GPCR Structure Therapeutics Inc. | 5.42% | 1,598,421 | $68.5M | Reduce -24.2% |
| AEROVATE THERAPEUTICS INC | 5.15% | 2,201,274 | $65.1M | No change |
| INHIBRX INC | 4.84% | 1,750,387 | $61.2M | No change |
| KROS Keros Therapeutics Inc. | 4.60% | 879,344 | $58.2M | New |
| GERN Geron Corp. | 4.54% | 17,391,639 | $57.4M | Reduce -25.6% |
| SVRA Savara Inc. | 3.94% | 10,000,000 | $49.8M | No change |
| OCUL Ocular Therapeutix Inc. | 3.83% | 5,319,148 | $48.4M | New |
| COGT Cogent Biosciences Inc. | 3.30% | 6,214,375 | $41.8M | Add +10.4% |
| EWTX Edgewise Therapeutics Inc. | 3.28% | 2,272,728 | $41.5M | New |
| MLYS Mineralys Therapeutics Inc. | 3.25% | 3,185,185 | $41.1M | New |
| MDGL Madrigal Pharmaceuticals Inc. | 3.15% | 149,283 | $39.9M | Reduce -17.0% |
| TRML Tourmaline Bio Inc. | 2.68% | 1,477,593 | $33.8M | Add +46.6% |
| TYRA Tyra Biosciences Inc. | 2.58% | 1,989,103 | $32.6M | No change |
| CMPS Compass Pathways PLC | 2.54% | 3,858,000 | $32.1M | No change |
| KURA Kura Oncology Inc. | 2.40% | 1,423,642 | $30.4M | No change |
| TARS Tarsus Pharmaceuticals Inc. | 2.28% | 793,829 | $28.9M | Reduce -30.5% |
| ADVM Adverum Biotechnologies Inc. | 2.25% | 2,008,340 | $28.4M | New |
| SLNO Soleno Therapeutics Inc. | 1.86% | 550,000 | $23.5M | New |
| CNTA Centessa Pharmaceuticals Ltd. | 1.82% | 2,040,816 | $23.1M | No change |
| ABVX Abivax SA-ADR | 1.24% | 1,100,000 | $15.7M | No change |
| VTGN Vistagen Therapeutics Inc. | 1.12% | 2,676,580 | $14.1M | No change |
| KALV Kalvista Pharmaceuticals Inc. | 1.09% | 1,163,356 | $13.8M | Reduce -65.7% |
| CCCC C4 Therapeutics Inc. | 0.82% | 1,276,574 | $10.4M | No change |
| TRDA Entrada Therapeutics Inc. | 0.66% | 584,955 | $8.3M | No change |
| ANTX AN2 Therapeutics Inc. | 0.40% | 1,555,118 | $5.1M | Reduce -41.9% |
| KOD Kodiak Sciences Inc. | 0.37% | 899,999 | $4.7M | Add +235.9% |
| VTYX Ventyx Biosciences Inc. | 0.35% | 815,724 | $4.5M | No change |
| NKTR Nektar Therapeutics | 0.30% | 4,000,000 | $3.7M | New |
| CABA Cabaletta Bio Inc. | 0.12% | 86,795 | $1.5M | Reduce -82.2% |
Portfolio Sells Q4 2023 → Q1 2024
| ICVX Icosavax Inc. | Sold out | 0.00% | −6.47 |
| RYZB Rayzebio Inc. | Sold out | 0.00% | −6.00 |
| ANTX AN2 Therapeutics Inc. | Reduce -41.9% | 0.40% | −5.69 |
| GRCL Gracell Biotechnologies-ADR | Sold out | 0.00% | −5.03 |
| GPCR Structure Therapeutics Inc. | Reduce -24.2% | 5.42% | −4.12 |
| KALV Kalvista Pharmaceuticals Inc. | Reduce -65.7% | 1.09% | −3.52 |
| MDGL Madrigal Pharmaceuticals Inc. | Reduce -17.0% | 3.15% | −1.47 |
| CABA Cabaletta Bio Inc. | Reduce -82.2% | 0.12% | −1.11 |
| GERN Geron Corp. | Reduce -25.6% | 4.54% | −0.93 |
| NRIX Nurix Therapeutics Inc. | Sold out | 0.00% | −0.82 |
| TSHA Taysha Gene Therapies Inc. | Sold out | 0.00% | −0.57 |
| TARS Tarsus Pharmaceuticals Inc. | Reduce -30.5% | 2.28% | −0.29 |
Portfolio Buys Q4 2023 → Q1 2024
| CGON CG Oncology Inc. | New | 12.39% | +12.39 |
| ATXS Astria Therapeutics Inc. | New | 5.87% | +5.87 |
| KROS Keros Therapeutics Inc. | New | 4.60% | +4.60 |
| OCUL Ocular Therapeutix Inc. | New | 3.83% | +3.83 |
| DYN Dyne Therapeutics Inc. | Add +60.6% | 5.95% | +3.51 |
| EWTX Edgewise Therapeutics Inc. | New | 3.28% | +3.28 |
| MLYS Mineralys Therapeutics Inc. | New | 3.25% | +3.25 |
| ADVM Adverum Biotechnologies Inc. | New | 2.25% | +2.25 |
| SLNO Soleno Therapeutics Inc. | New | 1.86% | +1.86 |
| SLN Silence Therapeutics PLC-ADR | Add +56.6% | 5.63% | +1.57 |
| NKTR Nektar Therapeutics | New | 0.30% | +0.30 |
| KOD Kodiak Sciences Inc. | Add +235.9% | 0.37% | +0.28 |
| TRML Tourmaline Bio Inc. | Add +46.6% | 2.68% | −0.25 |
| COGT Cogent Biosciences Inc. | Add +10.4% | 3.30% | −0.37 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 54 | $4.2B | ABVX, TNGX, CGON, COGT, IMVT |
| Q1 2026 | 49 | $3.5B | ABVX, CGON, TNGX, COGT, CNTA |
| Q4 2025 | 43 | $3.0B | ABVX, COGT, CGON, TNGX, CNTA |
| Q3 2025 | 40 | $2.0B | ABVX, CGON, COGT, AMLX, CNTA |
| Q2 2025 | 37 | $875.5M | CGON, TNGX, COGT, OCUL, CDTX |
| Q1 2025 | 37 | $733.1M | CGON, COGT, CNTA, MLYS, OCUL |
| Q4 2024 | 38 | $1.0B | CGON, DYN, XNCR, COGT, CNTA |
| Q3 2024 | 36 | $1.2B | CGON, DYN, COGT, ABVX, EWTX |
| Q2 2024 | 32 | $959.5M | CGON, DYN, ABVX, SLN, COGT |
| Q1 2024 | 33 | $1.3B | CGON, DYN, ATXS, SLN, GPCR |